secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rein Therapeutics, Inc. (RNTX)
CIK:        0001420565
Form:       8-K
Filed at:   2025-10-24T23:59:59+00:00
Accession:  0001193125-25-250175
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rein Therapeutics receives third $1.0M Pre-Paid Advance from Yorkville at 95% discount
--------------------------------------------------------------------------------

- Third Pre-Paid Advance of $1.0M on Oct 23, 2025; net proceeds $0.95M; total potential up to $6.0M.
- Interest accrues at 8% annually (18% on default); advances due 12 months from issuance.
- Yorkville may demand common stock issuance to offset outstanding balance; prior advances converted at avg prices ~$1.0562 and ~$1.0825 per share.
- First and Second Advances of $1.0M each previously drawn; combined shares issued: ~1.88M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420565/000119312525250175/0001193125-25-250175-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420565/000119312525250175/d13294d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-250175

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer